OnKure Therapeutics
Precision oncology company developing novel, highly selective PI3Kα inhibitors designed to overcome resistance mechanisms and provide better outcomes for cancer patients.
Location
Boulder, Colorado, USA
Founded
2019
Investors
1
Categories
biotech, oncology, pi3k-inhibitors, targeted-therapy
Notes
OnKure Therapeutics is a precision oncology company focused on developing next-generation PI3Kα inhibitors for cancer treatment. The company's approach aims to address the limitations of earlier PI3K inhibitors by developing more selective compounds with improved safety and efficacy profiles.
OnKure's lead programs target PI3Kα mutations that are common in breast cancer and other solid tumors, with the goal of overcoming resistance mechanisms that limit current therapies.
Team
- Jeffrey Stafford - Chief Executive Officer
- Valeria Fantin, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Founded in 2019 in Boulder, Colorado
- Focus on next-generation PI3Kα inhibitors for oncology
- Lead program OKT-001 targets PI3Kα-mutant cancers
- Designed to overcome limitations of earlier PI3K inhibitors
- Raised significant Series A and B funding
- Backed by top-tier healthcare investors
- Targeting breast cancer and other PI3Kα-mutant solid tumors
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |